Lobbying client
NEPHRON PHARMACEUTICALS CORPORATION
Developer and manufacturer of sterile inhalation and 503B outsourcing medication.
Filings
31
Filed by
1
Reported in-house
—
Reported by firms
$1,145,000
Reported lobbying by year
The larger of in-house and firm-reported each year, $ thousands
2018 to 2026
Filings
31 filings, newest first.
| Filing | Filed by | Amount |
|---|---|---|
|
3rd Quarter - Report 3rd Quarter 2026
|
THE VOGEL GROUP | $20,000 reported |
|
2nd Quarter - Report 2nd Quarter 2026
|
THE VOGEL GROUP | $50,000 reported |
|
1st Quarter - Report 1st Quarter 2026
|
THE VOGEL GROUP | $50,000 reported |
|
4th Quarter - Report 4th Quarter 2025
|
THE VOGEL GROUP | $50,000 reported |
|
3rd Quarter - Report 3rd Quarter 2025
|
THE VOGEL GROUP | $45,000 reported |
|
2nd Quarter - Report 2nd Quarter 2025
|
THE VOGEL GROUP | $45,000 reported |
|
1st Quarter - Report (No Activity) 1st Quarter 2025
|
THE VOGEL GROUP | — reported |
|
Registration - Amendment 2nd Quarter 2025
|
THE VOGEL GROUP | — reported |
|
2nd Quarter - Termination (No Activity) 2nd Quarter 2023
|
THE VOGEL GROUP | — reported |
|
1st Quarter - Report (No Activity) 1st Quarter 2023
|
THE VOGEL GROUP | — reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| THE VOGEL GROUP | 29 | $1,145,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Health Issues | HCR | 21 |
| Manufacturing | MAN | 15 |
| Pharmacy | PHA | 8 |
| Taxation/Internal Revenue Code | TAX | 1 |
Bills named in its filings
Bill numbers found in the filers' descriptions, most often named first.
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.